LLY

900.36

-0.41%↓

UNH

599.42

+1.06%↑

NVO

129.6

-1.65%↓

JNJ

167.6

+0.43%↑

ABBV

198.27

+0.95%↑

LLY

900.36

-0.41%↓

UNH

599.42

+1.06%↑

NVO

129.6

-1.65%↓

JNJ

167.6

+0.43%↑

ABBV

198.27

+0.95%↑

LLY

900.36

-0.41%↓

UNH

599.42

+1.06%↑

NVO

129.6

-1.65%↓

JNJ

167.6

+0.43%↑

ABBV

198.27

+0.95%↑

LLY

900.36

-0.41%↓

UNH

599.42

+1.06%↑

NVO

129.6

-1.65%↓

JNJ

167.6

+0.43%↑

ABBV

198.27

+0.95%↑

LLY

900.36

-0.41%↓

UNH

599.42

+1.06%↑

NVO

129.6

-1.65%↓

JNJ

167.6

+0.43%↑

ABBV

198.27

+0.95%↑

Home・Aktien・AcelRx Pharmaceuticals Inc

AcelRx Pharmaceuticals Inc

Open

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

Max

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+532.91 upside

AcelRx Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

9. Sept. 2024, 23:02 UTC

Top News

Ergebnisse

U.S. Dividends Grew 9% in the Second Quarter. Meta and Alphabet Gave a Boost. -- Barrons.com

9. Sept. 2024, 23:00 UTC

Akquisitionen, Fusionen, Übernahmen

U.S. Presses Its Antitrust Cases Against Google, Tapestry -- Barrons.com

9. Sept. 2024, 22:27 UTC

Market Talk

U.S. Solar-Panel Manufacturing Capacity Rises Four Fold in Two Years -- Market Talk

9. Sept. 2024, 22:19 UTC

Top News

Ergebnisse

Goldman CEO Solomon Expects Trading Revenue Drop in Third Quarter -- Barrons.com

9. Sept. 2024, 21:22 UTC

Top News

Don't Count Nvidia and the Rest of the Mag 7 Out Just Yet -- Barrons.com

9. Sept. 2024, 21:01 UTC

Top News

Incoming Starbucks CEO's Tall Order: Calming Anxious Employees -- Update

9. Sept. 2024, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

9. Sept. 2024, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

9. Sept. 2024, 20:48 UTC

Akquisitionen, Fusionen, Übernahmen

IBM to Acquire Accelalpha, an Oracle Consultancy

9. Sept. 2024, 20:44 UTC

Top News

Ergebnisse

Oracle 1Q Profit, Rev Rise Amid Additional AI Contract Wins

9. Sept. 2024, 20:40 UTC

Top News

Dow, S&P 500 Rise More Than 1% to Start the Week -- WSJ

9. Sept. 2024, 20:32 UTC

Akquisitionen, Fusionen, Übernahmen

IBM to Acquire Accelalpha, Leading Oracle Consultancy >IBM

9. Sept. 2024, 20:32 UTC

Akquisitionen, Fusionen, Übernahmen

IBM: Accelalpha Will Join IBM Consulting >IBM

9. Sept. 2024, 20:32 UTC

Akquisitionen, Fusionen, Übernahmen

IBM: Acquisition Expands IBM's Oracle Consulting Expertise in Supply Chain and Logistics, Finance, Enterprise Performance Management

9. Sept. 2024, 20:32 UTC

Akquisitionen, Fusionen, Übernahmen

IBM Didn't Disclose Financial Details of Accelalpha Acquisition >IBM

9. Sept. 2024, 20:31 UTC

Top News

DirecTV Subscribers Might Miss 'Monday Night Football' as Fight With Disney Drags On -- WSJ

9. Sept. 2024, 20:31 UTC

Top News

Dow, S&P 500 Rise More Than 1% to Start the Week -- WSJ

9. Sept. 2024, 20:30 UTC

Top News

Norfolk Southern CEO Expected to Depart Amid Board Probe -- WSJ

9. Sept. 2024, 20:30 UTC

Akquisitionen, Fusionen, Übernahmen

IBM to Acquire Accelalpha, Leading Oracle Consultancy

9. Sept. 2024, 20:30 UTC

Akquisitionen, Fusionen, Übernahmen

IBM To Acquire Accelalpha, Leading Oracle Consultancy >IBM

9. Sept. 2024, 20:22 UTC

Ergebnisse

Oracle Stock Jumps On Earnings Beat, Amazon Partnership -- IBD

9. Sept. 2024, 20:17 UTC

Ergebnisse

Oracle Earnings Beat Estimates. The Stock Is Rising. -- Barrons.com

9. Sept. 2024, 20:06 UTC

Ergebnisse

Oracle: Strong Contract Backlog to Increase Revenue Growth Throughout FY25 >ORCL

9. Sept. 2024, 20:05 UTC

Ergebnisse

Oracle 1Q Hardware Revenue $655M >ORCL

9. Sept. 2024, 20:05 UTC

Ergebnisse

Oracle 1Q Rev $13.31B >ORCL

9. Sept. 2024, 20:05 UTC

Ergebnisse

Oracle 1Q Cloud License and On-Premise License Revenue $870M >ORCL

9. Sept. 2024, 20:05 UTC

Ergebnisse

Oracle 1Q Services Revenue $1.26B >ORCL

9. Sept. 2024, 20:05 UTC

Ergebnisse

Oracle 1Q Cloud Services and License Support Revenue $10.52B >ORCL

9. Sept. 2024, 20:05 UTC

Ergebnisse

Oracle 1Q Adj EPS $1.39 >ORCL

9. Sept. 2024, 20:05 UTC

Ergebnisse

Oracle 1Q Net $2.9B >ORCL

Peer-Vergleich

Kursveränderung

AcelRx Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

532.91% Vorteil

12-Monats-Prognose

Durchschnitt 5 USD 532.91%

Hoch 5 USD

Tief 5 USD

Basierend auf 1 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für AcelRx Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

1 ratings

Buy

Halten

Sell

Basierend auf 1 Analysten, die in den letzten 3 Monaten Aktienbewertungen für AcelRx Pharmaceuticals Inc – Dist abgegeben haben.

Andere Aktien aus dem Sektor

LLY

Eli Lilly and Co.

900.36

↓-0.41%

UNH

UnitedHealth Group Inc

599.42

↑ +1.06%

NVO

Novo Nordisk A-S

129.6

↓-1.65%

JNJ

Johnson and Johnson

167.6

↑ +0.43%

ABBV

AbbVie Inc

198.27

↑ +0.95%

AcelRx Pharmaceuticals Inc

Übersicht

Veränderung der Aktienkurses

Empfehlungen

AcelRx Pharmaceuticals Inc Chart

Ähnliche Nachrichten

Peer-Vergleich

AcelRx Pharmaceuticals Inc Prognose

Kursziel

Rating-Konsens

Andere Aktien aus dem Sektor